Legend Biotech is reportedly considering a secondary listing outside the United States, with potential listing locations including Hong Kong

According to informed sources, Legend Biotech is considering a secondary listing outside the United States due to strong interest from investors in the pharmaceutical company. Possible listing locations include Hong Kong, Singapore, and London, the sources said. They noted that the relevant considerations are still ongoing, and Legend Biotech may decide not to proceed with a secondary listing. A representative of Legend Biotech declined to comment